Is Astrana Health, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Astrana Health, Inc. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company appears to be overvalued based on its P/E ratio of 36, which is substantially higher than peers like Premier, Inc. at 11.29 and Select Medical Holdings Corp. at 7.26. Additionally, the EV to EBITDA ratio of 14.41 further supports this assessment, as it is elevated compared to the industry standards.
The company's return metrics also reflect its struggles, particularly with a one-year return of -47.84%, contrasting sharply with the S&P 500's gain of 14.08% during the same period. This underperformance, combined with the very expensive valuation grade, suggests that Astrana Health, Inc. is currently overvalued in the market.